Intuitive Surgical Stock Rating Adjusted as Analysts Weigh In

Intuitive Surgical (NASDAQ: ISRG) faced a notable shift in its stock rating as Zacks Research downgraded it from a “strong-buy” to a “hold” on January 17, 2024. This modification reflects a broader analysis landscape, with various equities analysts providing mixed assessments of the medical technology company’s performance.

In recent evaluations, Wall Street Zen upgraded Intuitive Surgical from a “hold” to a “buy” rating, while Mizuho set a price target of $575.00. The Goldman Sachs Group reaffirmed a “buy” rating, issuing a price target of $714.00. Additionally, Evercore ISI set a target price of $580.00 for the company. Overall, one analyst rated the stock as a “strong buy,” while sixteen assigned a “buy” rating, nine labeled it as “hold,” and one issued a “sell” rating. According to data from MarketBeat.com, Intuitive Surgical currently holds an average rating of “Moderate Buy” with a consensus price target of $621.83.

Recent Earnings Performance

Intuitive Surgical released its quarterly earnings results on January 22, 2024. The company reported earnings per share (EPS) of $2.53, exceeding analysts’ expectations of $2.27 by $0.26. The firm achieved a net margin of 28.58% and a return on equity of 15.08%. Revenue for the quarter reached $2.87 billion, surpassing forecasts of $2.72 billion. This represents an 18.8% increase in quarterly revenue compared to the same period last year, where the company reported an EPS of $2.21. Analysts anticipate that Intuitive Surgical will post an EPS of $6.43 for the current year.

Insider Transactions and Institutional Activity

In related developments, insider trading activity has raised eyebrows. On December 1, 2023, insider Gary S. Guthart sold 22,806 shares at an average price of $570.89, totaling approximately $13 million. Following this transaction, Guthart retained 2,694 shares valued at around $1.5 million, indicating a significant 89.44% reduction in his position.

Similarly, Mark Brosius, Senior Vice President, sold 4,500 shares on December 12, 2023, at an average price of $547.36, amounting to $2.5 million. Following this sale, Brosius held 907 shares valued at approximately $496,455.52, reflecting an 83.23% decrease in his holdings. Over the past three months, insiders have sold a total of 55,714 shares worth about $31.6 million.

Institutional investors have also been active in the stock. Notably, Riversedge Advisors increased its holdings by 1.9%, owning 901 shares valued at approximately $510,000. Fiduciary Financial Group raised its position by 2.1%, owning 920 shares worth $521,000. Meanwhile, Activest Wealth Management boosted its stake by 21.7%, acquiring 112 shares valued at $50,000. Currently, institutional investors and hedge funds hold 83.64% of Intuitive Surgical’s stock.

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, specializes in robotic-assisted surgical systems. Its flagship product, the da Vinci surgical system, facilitates minimally invasive procedures by translating a surgeon’s movements into precise motions of small instruments within the patient. The company provides hospitals and surgical centers with systems, instruments, and related technologies aimed at enhancing precision and control in surgical environments.

As analysts continue to evaluate Intuitive Surgical’s prospects, its stock remains a focal point for investors seeking insights into the medical technology sector.